Evidence map›Paper›PMID 31754252›Full record

ArticleBone marrow transplantation2020

Clinical characteristics of human herpesvirus-6 myelitis after allogeneic hematopoietic stem cell transplantation and its favorable outcome by early intervention.

Kohei Shiroshita, Takehiko Mori, Jun Kato, Masatoshi Sakurai, Yuya Koda, Ryohei Abe, Koichi Murakami, Chieko Sumiya, Shinya Fujita, Kentaro Yamaguchi and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Usefulness of the FilmArray Meningitis/Encephalitis Panel in diagnosis of central nervous system infection after allogeneic hematopoietic stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Kohei ShiroshitaDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Takehiko MoriDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. tmori@a3.keio.jp.ORCID http://orcid.org/0000-0002-8176-4760
Jun KatoDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0003-1869-5480
Masatoshi SakuraiDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-6687-4136
Yuya KodaDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Ryohei AbeDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Koichi MurakamiDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Chieko SumiyaDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Shinya FujitaDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Kentaro YamaguchiDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Rie YamazakiDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Hitomi NakayamaDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Shigeaki SuzukiDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Jin NakaharaDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Shinichiro OkamotoDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Keio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After allogeneic hematopoietic stem cell transplantation (HSCT), human herpesvirus-6 (HHV-6) can cause serious central nervous system (CNS) disorder and typically presents as encephalitis. Another manifestation of HHV-6 is myelitis, which has not been fully evaluated. In this study, we retrospectively analyzed 19 patients who developed HHV-6 myelitis after allogeneic HSCT. Median onset was 20 days after transplantation (range, 13-31), with a cumulative incidence of 4.1% at day 40 after transplantation. Median age at transplant was 50 years (range, 17-61). Median copy number of HHV-6 DNA was 3000 copies/ml in cerebrospinal fluid (CSF; range, 200-100,000). The most common symptoms were pruritus, pain of the extremities/back, and numbness. Three patients subsequently developed encephalitis in the clinical course of myelitis; their HHV-6 copy numbers in CSF had been higher than 10,000 copies/ml at the onset of myelitis. Antiviral agents were initiated shortly after onset in all patients, resulting in recovery. These results suggest that myelitis would be an important subtype of HHV-6-associated CNS disorders after allogeneic HSCT, whose prognosis could be favorable by an early intervention. Transplant physicians should recognize early posttransplant neurological symptoms such as pruritus, pain, or numbness as possible signs of HHV-6 myelitis, which could also progress to encephalitis.

Indexed as

Encephalitis, ViralHematopoietic Stem Cell TransplantationHerpesvirus 6, HumanMyelitisRoseolovirus InfectionsDNA, ViralHumansRetrospective StudiesDNA, Viral

Identifiers

PMID31754252
OpenAlexW2991014474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.